Lawyers argue Bankman-Fried needs more Adderall in order to participate in trial
The post Lawyers argue Bankman-Fried needs more Adderall in order to participate in trial appeared on BitcoinEthereumNews.com. According to a recent court letter, Samuel Bankman-Fried has reportedly faced difficulties concentrating during his ongoing criminal trial due to being denied access to his prescribed ADHD medication. As Cohen & Gresser LLP stated in a letter to Judge Lewis A. Kaplan dated Oct. 15, Bankman-Fried takes a prescribed dose of Adderall for attentional issues but has been unable to take it during trial hours for the past two weeks. The letter asserts that without access to his medication, Bankman-Fried “has not been able to concentrate at the level he ordinarily would,” raising concerns about his ability to participate as the defense presents its case meaningfully. According to the letter, Bankman-Fried has been given one dose early in the morning before being transported to the courthouse, which wears off before the trial starts. He does not receive another dose until returning to jail in the evening after proceedings conclude for the day. To address the issue, the court proposed giving Bankman-Fried an extended-release 20mg dose of Adderall on Monday morning before the trial resumes. However, the defense expressed uncertainty about whether the Bureau of Prisons could provide this and whether it would be effective if administered. As a result, they requested either adjourning Tuesday’s proceedings to resolve the matter or permitting counsel to provide Bankman-Fried’s medication in court. The court has not yet issued a ruling on the request. Mental health medication under custody While defendants are subject to restrictions while in custody, medical experts and advocacy groups have argued that denying necessary medication can impair an individual’s ability to participate in their defense actively. For example, the American Bar Association (ABA) has previously expressed concerns about detention facilities restricting prescribed mental health drugs, saying this violates rights and compromises a defendant’s competency to stand trial. However, correctional facilities often…
The post Lawyers argue Bankman-Fried needs more Adderall in order to participate in trial appeared on BitcoinEthereumNews.com.
According to a recent court letter, Samuel Bankman-Fried has reportedly faced difficulties concentrating during his ongoing criminal trial due to being denied access to his prescribed ADHD medication. As Cohen & Gresser LLP stated in a letter to Judge Lewis A. Kaplan dated Oct. 15, Bankman-Fried takes a prescribed dose of Adderall for attentional issues but has been unable to take it during trial hours for the past two weeks. The letter asserts that without access to his medication, Bankman-Fried “has not been able to concentrate at the level he ordinarily would,” raising concerns about his ability to participate as the defense presents its case meaningfully. According to the letter, Bankman-Fried has been given one dose early in the morning before being transported to the courthouse, which wears off before the trial starts. He does not receive another dose until returning to jail in the evening after proceedings conclude for the day. To address the issue, the court proposed giving Bankman-Fried an extended-release 20mg dose of Adderall on Monday morning before the trial resumes. However, the defense expressed uncertainty about whether the Bureau of Prisons could provide this and whether it would be effective if administered. As a result, they requested either adjourning Tuesday’s proceedings to resolve the matter or permitting counsel to provide Bankman-Fried’s medication in court. The court has not yet issued a ruling on the request. Mental health medication under custody While defendants are subject to restrictions while in custody, medical experts and advocacy groups have argued that denying necessary medication can impair an individual’s ability to participate in their defense actively. For example, the American Bar Association (ABA) has previously expressed concerns about detention facilities restricting prescribed mental health drugs, saying this violates rights and compromises a defendant’s competency to stand trial. However, correctional facilities often…
What's Your Reaction?
